nach oben

Breast Cancer Research

Erschienen in:

01.12.2010 | Section introduction

Session 6 introduction

verfasst von: John FR Robertson, Per Eystein Lønning

Erschienen in: Breast Cancer Research | Sonderheft 4/2010

Einloggen, um Zugang zu erhalten

Excerpt

Session 6 was entitled 'Who would have thought it!' and comprised four separate presentations that had in common that the inferred conclusions of their titles would not necessarily have been inferred from perceived wisdom. …

Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM: Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 1989, 49: 2175-2183.PubMed

Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004, 85: 151-159. 10.1023/B:BREA.0000025406.31193.e8.CrossRefPubMed

Aubert RE, Stanek EJ, Yao J, Teagarden JR, Subar M, Epstein RS, Skaar TC, Desta Z, Flockhart DA: Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol. 2009, 27: 18s-10.1200/JCO.2009.22.4626.CrossRef

Dezentjé VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, Egberts AC, Nortier JW, Guchelaar HJ: Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol. 2010, 28: 2423-2429. 10.1200/JCO.2009.25.0894.CrossRefPubMed

Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Paszat LF: Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010, 340: c693-10.1136/bmj.c693.CrossRefPubMedPubMedCentral

Folkman J, Hahnfeldt P, Hlatky L: Cancer: looking outside the genome. Nat Rev Mol Cell Biol. 2000, 1: 76-79. 10.1038/35036100.CrossRefPubMed

O'Shaughnessy J, Miles D, Gray RJ, Dieras V, Perez EA, Zon R, et al: A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol. 2010, 28 (Suppl): 15s-(abstr 1005)

Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD, ECOG 2100: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008, 26: 4672-4678. 10.1200/JCO.2008.16.1612.CrossRefPubMedPubMedCentral

Titel: Session 6 introduction
verfasst von: John FR Robertson
Per Eystein Lønning
Publikationsdatum: 01.12.2010
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe Sonderheft 4/2010
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr2744

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Session 6 introduction

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 4/2010

Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations

Emerging breast cancer epidemic: evidence from Africa

Are current development programs realising the full potential of new agents?

Emerging breast cancer epidemic: impact on palliative care

Contribution of biomarkers to personalized medicine

Breast cancer prevention in the developing world

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie